HC Wainwright & Co. Maintains Buy on Cognition Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Cognition Therapeutics (NASDAQ:CGTX) but lowered the price target from $7 to $5.
August 12, 2024 | 9:56 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Cognition Therapeutics but lowered the price target from $7 to $5.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates a more cautious outlook on its short-term performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100